BMRN vs. ALNY, UTHR, IONS, MDGL, ALKS, TEVA, BGNE, VTRS, SRPT, and GMAB
Should you be buying BioMarin Pharmaceutical stock or one of its competitors? The main competitors of BioMarin Pharmaceutical include Alnylam Pharmaceuticals (ALNY), United Therapeutics (UTHR), Ionis Pharmaceuticals (IONS), Madrigal Pharmaceuticals (MDGL), Alkermes (ALKS), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Viatris (VTRS), Sarepta Therapeutics (SRPT), and Genmab A/S (GMAB). These companies are all part of the "pharmaceutical preparations" industry.
Alnylam Pharmaceuticals (NASDAQ:ALNY) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, community ranking, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.
Alnylam Pharmaceuticals has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.34, indicating that its share price is 66% less volatile than the S&P 500.
BioMarin Pharmaceutical received 445 more outperform votes than Alnylam Pharmaceuticals when rated by MarketBeat users. However, 76.17% of users gave Alnylam Pharmaceuticals an outperform vote while only 74.70% of users gave BioMarin Pharmaceutical an outperform vote.
Alnylam Pharmaceuticals presently has a consensus price target of $216.19, indicating a potential upside of 44.70%. BioMarin Pharmaceutical has a consensus price target of $106.11, indicating a potential upside of 36.80%. Given BioMarin Pharmaceutical's stronger consensus rating and higher possible upside, equities analysts clearly believe Alnylam Pharmaceuticals is more favorable than BioMarin Pharmaceutical.
BioMarin Pharmaceutical has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
BioMarin Pharmaceutical has a net margin of 8.31% compared to BioMarin Pharmaceutical's net margin of -16.58%. Alnylam Pharmaceuticals' return on equity of 5.34% beat BioMarin Pharmaceutical's return on equity.
In the previous week, BioMarin Pharmaceutical had 22 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 31 mentions for BioMarin Pharmaceutical and 9 mentions for Alnylam Pharmaceuticals. BioMarin Pharmaceutical's average media sentiment score of 0.33 beat Alnylam Pharmaceuticals' score of 0.27 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.
93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 1.9% of BioMarin Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
BioMarin Pharmaceutical beats Alnylam Pharmaceuticals on 12 of the 18 factors compared between the two stocks.
Get BioMarin Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioMarin Pharmaceutical Competitors List
Related Companies and Tools
